Dr. Apolo on Updated JAVELIN Results of Avelumab in Urothelial Carcinoma

Andrea B. Apolo, MD
Published: Sunday, Jun 04, 2017



Andrea B. Apolo, MD, principal investigator and the head of the Bladder Cancer Section in the Genitourinary Malignancies Branch at the National Cancer Institute’s Center for Cancer Research, discusses the updated findings of the phase Ib JAVELIN trial exploring avelumab (Bavencio) for the treatment of patients with metastatic urothelial carcinoma.

<<< View more from the 2017 ASCO Annual Meeting


Andrea B. Apolo, MD, principal investigator and the head of the Bladder Cancer Section in the Genitourinary Malignancies Branch at the National Cancer Institute’s Center for Cancer Research, discusses the updated findings of the phase Ib JAVELIN trial exploring avelumab (Bavencio) for the treatment of patients with metastatic urothelial carcinoma.

<<< View more from the 2017 ASCO Annual Meeting

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Year in Review™: Reflecting on Recent Evidence for the Treatment of Hematologic MalignanciesFeb 28, 20192.0
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Publication Bottom Border
Border Publication
x